415 related articles for article (PubMed ID: 32560607)
1. The Roles of Alternative Splicing in Tumor-immune Cell Interactions.
Wang Y; Zhang H; Jiao B; Nie J; Li X; Wang W; Wang H
Curr Cancer Drug Targets; 2020; 20(10):729-740. PubMed ID: 32560607
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of HNRNPA1 induced neoantigen generation via regulating alternative splicing.
Sun Y; Xiong B; Shuai X; Li J; Wang C; Guo J; Cheng Z; Liu S
Mol Med; 2024 Jun; 30(1):85. PubMed ID: 38867190
[TBL] [Abstract][Full Text] [Related]
3. Alternative tumour-specific antigens.
Smith CC; Selitsky SR; Chai S; Armistead PM; Vincent BG; Serody JS
Nat Rev Cancer; 2019 Aug; 19(8):465-478. PubMed ID: 31278396
[TBL] [Abstract][Full Text] [Related]
4.
Zhang Z; Zhou C; Tang L; Gong Y; Wei Z; Zhang G; Wang F; Liu Q; Yu J
Aging (Albany NY); 2020 Jul; 12(14):14633-14648. PubMed ID: 32697765
[TBL] [Abstract][Full Text] [Related]
5. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
6. Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development.
Cheng R; Xu Z; Luo M; Wang P; Cao H; Jin X; Zhou W; Xiao L; Jiang Q
Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35279714
[TBL] [Abstract][Full Text] [Related]
7. Sources of Cancer Neoantigens beyond Single-Nucleotide Variants.
Capietto AH; Hoshyar R; Delamarre L
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077528
[TBL] [Abstract][Full Text] [Related]
8. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
9. A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens.
Minati R; Perreault C; Thibault P
Front Immunol; 2020; 11():583287. PubMed ID: 33424836
[TBL] [Abstract][Full Text] [Related]
10. Developing neoantigen-targeted T cell-based treatments for solid tumors.
Yamamoto TN; Kishton RJ; Restifo NP
Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
[TBL] [Abstract][Full Text] [Related]
11. [Cancer immunotherapy targeting neoantigens derived from tumor-specific gene mutations].
Sasada T
Nihon Rinsho; 2017 Feb; 75(2):189-195. PubMed ID: 30562851
[TBL] [Abstract][Full Text] [Related]
12. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
Lam H; McNeil LK; Starobinets H; DeVault VL; Cohen RB; Twardowski P; Johnson ML; Gillison ML; Stein MN; Vaishampayan UN; DeCillis AP; Foti JJ; Vemulapalli V; Tjon E; Ferber K; DeOliveira DB; Broom W; Agnihotri P; Jaffee EM; Wong KK; Drake CG; Carroll PM; Davis TA; Flechtner JB
Cancer Discov; 2021 Mar; 11(3):696-713. PubMed ID: 33504579
[TBL] [Abstract][Full Text] [Related]
13. Neoantigens in cancer immunotherapy.
Schumacher TN; Schreiber RD
Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
[TBL] [Abstract][Full Text] [Related]
14. Targeting neoantigens to augment antitumour immunity.
Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
16. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Hurwitz AA; Watkins SK
Cancer Immunol Immunother; 2012 Feb; 61(2):289-293. PubMed ID: 22237887
[TBL] [Abstract][Full Text] [Related]
17. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
18. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
19. Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy.
Cerezo-Wallis D; Soengas MS
Curr Pharm Des; 2016; 22(41):6234-6250. PubMed ID: 27568731
[TBL] [Abstract][Full Text] [Related]
20. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
Wang Y; Shi T; Song X; Liu B; Wei J
Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
